Inflammation and ischemia: Macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes

JoAnn Trial, Roger D. Rossen, Jose Rubio, Anne A Knowlton

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Proteolytic enzymes, released early in the course of an inflammatory response, hydrolyze fibronectin, producing fragments of the parent molecule that alter monocyte phenotype and migratory behavior. Here we test the hypothesis that macrophages, stimulated by the dominant 110-120 kd fibronectin fragments (FNf), as are found in lymphatic fluid draining sites of cardiac ischemia-reperfusion injury, produce factors that promote the survival of injured parenchymal cells. Rat splenic macrophages stimulated in vitro with purified FNf produced soluble factors that protected hypoxic rat cardiac myocytes from death by apoptosis. Addition of blocking antibodies specific for tumor necrosis factor-α (TNF-α), fibroblast growth factor-1 (FGF-1), insulin-like growth factor I (IGF-I), and leukemia inhibitory factor (LIF) partly reduced the protection against apoptosis provided to hypoxic cardiac myocytes by cell-free culture supernatants from FNf-stimulated macrophages. Complete blockade of this protection was achieved by a combination of antibodies specific for FGF-1, IGF-I, and LIF. Stimulation of human monocyte-derived macrophages in vitro with FNf significantly increased their output of TNF-α, FGF-1, IGF-I, and LIF. These results suggest that tissue degradation products, released in the early hours of an inflammatory response, stimulate tissue-infiltrating macrophages to protect injured but still viable parenchymal cells from death by apoptosis.

Original languageEnglish (US)
Pages (from-to)538-545
Number of pages8
JournalExperimental Biology and Medicine
Volume229
Issue number6
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Macrophages
Fibronectins
Cardiac Myocytes
Leukemia Inhibitory Factor
Ischemia
Fibroblast Growth Factor 1
Inflammation
Insulin-Like Growth Factor I
Survival
Apoptosis
Rats
Tumor Necrosis Factor-alpha
Tissue
Blocking Antibodies
Reperfusion Injury
Cell culture
Monocytes
Peptide Hydrolases
Cell Death
Cell Culture Techniques

Keywords

  • Apoptosis
  • Cytokines
  • Fibronectin
  • Ischemia
  • Monocytes/macrophages

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Inflammation and ischemia : Macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. / Trial, JoAnn; Rossen, Roger D.; Rubio, Jose; Knowlton, Anne A.

In: Experimental Biology and Medicine, Vol. 229, No. 6, 06.2004, p. 538-545.

Research output: Contribution to journalArticle

@article{143c54a408d54a8f96b0774e7c8532d1,
title = "Inflammation and ischemia: Macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes",
abstract = "Proteolytic enzymes, released early in the course of an inflammatory response, hydrolyze fibronectin, producing fragments of the parent molecule that alter monocyte phenotype and migratory behavior. Here we test the hypothesis that macrophages, stimulated by the dominant 110-120 kd fibronectin fragments (FNf), as are found in lymphatic fluid draining sites of cardiac ischemia-reperfusion injury, produce factors that promote the survival of injured parenchymal cells. Rat splenic macrophages stimulated in vitro with purified FNf produced soluble factors that protected hypoxic rat cardiac myocytes from death by apoptosis. Addition of blocking antibodies specific for tumor necrosis factor-α (TNF-α), fibroblast growth factor-1 (FGF-1), insulin-like growth factor I (IGF-I), and leukemia inhibitory factor (LIF) partly reduced the protection against apoptosis provided to hypoxic cardiac myocytes by cell-free culture supernatants from FNf-stimulated macrophages. Complete blockade of this protection was achieved by a combination of antibodies specific for FGF-1, IGF-I, and LIF. Stimulation of human monocyte-derived macrophages in vitro with FNf significantly increased their output of TNF-α, FGF-1, IGF-I, and LIF. These results suggest that tissue degradation products, released in the early hours of an inflammatory response, stimulate tissue-infiltrating macrophages to protect injured but still viable parenchymal cells from death by apoptosis.",
keywords = "Apoptosis, Cytokines, Fibronectin, Ischemia, Monocytes/macrophages",
author = "JoAnn Trial and Rossen, {Roger D.} and Jose Rubio and Knowlton, {Anne A}",
year = "2004",
month = "6",
language = "English (US)",
volume = "229",
pages = "538--545",
journal = "Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)",
issn = "1535-3702",
publisher = "Society for Experimental Biology and Medicine",
number = "6",

}

TY - JOUR

T1 - Inflammation and ischemia

T2 - Macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes

AU - Trial, JoAnn

AU - Rossen, Roger D.

AU - Rubio, Jose

AU - Knowlton, Anne A

PY - 2004/6

Y1 - 2004/6

N2 - Proteolytic enzymes, released early in the course of an inflammatory response, hydrolyze fibronectin, producing fragments of the parent molecule that alter monocyte phenotype and migratory behavior. Here we test the hypothesis that macrophages, stimulated by the dominant 110-120 kd fibronectin fragments (FNf), as are found in lymphatic fluid draining sites of cardiac ischemia-reperfusion injury, produce factors that promote the survival of injured parenchymal cells. Rat splenic macrophages stimulated in vitro with purified FNf produced soluble factors that protected hypoxic rat cardiac myocytes from death by apoptosis. Addition of blocking antibodies specific for tumor necrosis factor-α (TNF-α), fibroblast growth factor-1 (FGF-1), insulin-like growth factor I (IGF-I), and leukemia inhibitory factor (LIF) partly reduced the protection against apoptosis provided to hypoxic cardiac myocytes by cell-free culture supernatants from FNf-stimulated macrophages. Complete blockade of this protection was achieved by a combination of antibodies specific for FGF-1, IGF-I, and LIF. Stimulation of human monocyte-derived macrophages in vitro with FNf significantly increased their output of TNF-α, FGF-1, IGF-I, and LIF. These results suggest that tissue degradation products, released in the early hours of an inflammatory response, stimulate tissue-infiltrating macrophages to protect injured but still viable parenchymal cells from death by apoptosis.

AB - Proteolytic enzymes, released early in the course of an inflammatory response, hydrolyze fibronectin, producing fragments of the parent molecule that alter monocyte phenotype and migratory behavior. Here we test the hypothesis that macrophages, stimulated by the dominant 110-120 kd fibronectin fragments (FNf), as are found in lymphatic fluid draining sites of cardiac ischemia-reperfusion injury, produce factors that promote the survival of injured parenchymal cells. Rat splenic macrophages stimulated in vitro with purified FNf produced soluble factors that protected hypoxic rat cardiac myocytes from death by apoptosis. Addition of blocking antibodies specific for tumor necrosis factor-α (TNF-α), fibroblast growth factor-1 (FGF-1), insulin-like growth factor I (IGF-I), and leukemia inhibitory factor (LIF) partly reduced the protection against apoptosis provided to hypoxic cardiac myocytes by cell-free culture supernatants from FNf-stimulated macrophages. Complete blockade of this protection was achieved by a combination of antibodies specific for FGF-1, IGF-I, and LIF. Stimulation of human monocyte-derived macrophages in vitro with FNf significantly increased their output of TNF-α, FGF-1, IGF-I, and LIF. These results suggest that tissue degradation products, released in the early hours of an inflammatory response, stimulate tissue-infiltrating macrophages to protect injured but still viable parenchymal cells from death by apoptosis.

KW - Apoptosis

KW - Cytokines

KW - Fibronectin

KW - Ischemia

KW - Monocytes/macrophages

UR - http://www.scopus.com/inward/record.url?scp=2942525749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942525749&partnerID=8YFLogxK

M3 - Article

C2 - 15169973

AN - SCOPUS:2942525749

VL - 229

SP - 538

EP - 545

JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)

SN - 1535-3702

IS - 6

ER -